AbbVie, Teva Accused Of Pay-For-Delay On Generic Niaspan

Law360, New York (April 4, 2013, 8:34 PM EDT) -- A union pension fund lodged an antitrust class action Thursday accusing AbbVie Inc. of paying off Teva Pharmaceuticals USA Inc. in a sham patent settlement to delay the release of a generic version of the cholesterol drug Niaspan.

The lawsuit, filed by the United Food & Commercial Workers Union and Midwest Health Benefits Fund, says collusion between AbbVie and generics maker Teva has kept a cheaper, nonbranded version of Niaspan off the market for eight years and driven up the price for end-purchasers.

So-called pay-for-delay cases...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.